Drug-eluting particles for interventional pharmacology.
Chemoembolization with drug-eluting particles has been recently introduced in the field of interventional oncology. In this review, we will describe the pharmacokinetic properties and efficacy of all commercially available or under investigation drug-eluting particles and discuss the potentials and future of this new form of transcatheter arterial therapy for liver cancer.
The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, MD, USA.
Eleni
E
Liapi
Kwang-Hun
KH
Lee
Christos C
CC
Georgiades
Kelvin
K
Hong
Jean-Francois H
JF
Geschwind
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000628:therapy; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000556:secondary / Q000628:therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008863:Microspheres
D000970:Antineoplastic Agents; D004337:Drug Carriers; D000077146:Irinotecan; D004317:Doxorubicin; D002166:Camptothecin